Recent Advances in the Management of Epilepsy: Expert Treatment Strategies for Improving Clinical and Economic Outcomes

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session from the 2020 Spring Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive

This activity is valid from June 1, 2020 to June 1, 2021

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation, and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post-test to receive continuing education credits. If you do not pass the post-test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post-test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.


Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by an educational grant from Eisai

Epilepsy is a chronic neurological disorder where the nerve cell activity in the brain becomes disrupted, causing seizures or periods of unusual behavior. Epilepsy affects about 3 million people in the United States and accounts for about $15 billion in medical costs. For about 70 percent of those diagnosed with epilepsy, seizures can be controlled with medications and different surgical techniques. Some drugs are more effective for specific types of seizures. Patients who experience seizures, particularly those that are not easily controlled, need to seek out neurological guidance. The goal for neurologists is to achieve a seizure-free status for their patients without adverse effects. With that said there are still around 60% of patients that require treatment with anticonvulsants.

The diagnosis of epileptic seizures is made by analyzing the patient's clinical history as well as performing neurophysiological and neuroimaging tests. Treatment of epilepsy involves reducing the number of seizures by administering various antiepileptic drugs (AEDs). This approach requires long-term adherence from patients. Unfortunately, more than one-third of people who experience seizures continue to have issues despite the medication given. Many patients do not have all the treatments available to them because their seizures are not adequately controlled, or because they experience severe adverse effects. The development of new AEDs continues to increase and drug therapies can now be individualized to the patient’s symptoms and needs. It is also important to understand the mechanisms of action and the pharmacokinetics of antiepileptic drugs so that these agents can be used effectively in clinical practice, especially in the combined therapeutic strategies. Despite many of the available AED options, there is still a need for medications with novel mechanisms of action that are effective and well tolerated. Uncontrolled seizures and their associated comorbidities, such as depression, can have detrimental effects on the patient’s quality of life.

Upon completion of this activity, participants will be able to:

  • Differentiate current and emerging antiepileptic drugs (AEDs) based on the latest evidence for their efficacy, safety, and adherence potential

  • Develop optimal diagnostic goals for patients with epilepsy, including the impact of genetic diagnostics

  • Assess the latest guideline recommendations and clinical evidence to develop optimal personalized treatment strategies for patients with epilepsy

  • Identify and overcome challenges of epilepsy management with the goal of reducing seizure burden, improving adherence and reducing adverse events

  • Analyze the managed care considerations of current and emerging therapies by exploring where these agents fit in the epilepsy management paradigm therapies in relapsed/refractory multiple myeloma management in order to improve patient adherence


Faculty: Joseph I. Sirven, MD
Professor, Chair Emeritus
Division of Epilepsy
Department of Neurology
Mayo Clinic in Florida


Dr. Sirven serves as a consultant for Neurelis, GW Pharma, UCB Pharma, Neuropace Inc., SK Pharma, Otsuka, Department of Defense, and the Federal Aviation Authority. He has received grants/research support from UCB, Biogen, and Eisai. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships to disclose.
Will Williams has no relevant financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in nursing continuing professional development.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This presentation is supported by an educational grant from Eisai

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue